AR020063A1 - Oximil e hidroxilamino c, prostaglandinas utiles como agonistas de receptores fp y su uso para fabricar medicamentos para tratar oseos y glaucoma. - Google Patents
Oximil e hidroxilamino c, prostaglandinas utiles como agonistas de receptores fp y su uso para fabricar medicamentos para tratar oseos y glaucoma.Info
- Publication number
- AR020063A1 AR020063A1 ARP990101444A ARP990101444A AR020063A1 AR 020063 A1 AR020063 A1 AR 020063A1 AR P990101444 A ARP990101444 A AR P990101444A AR P990101444 A ARP990101444 A AR P990101444A AR 020063 A1 AR020063 A1 AR 020063A1
- Authority
- AR
- Argentina
- Prior art keywords
- monocyclic
- ring
- aliphatic ring
- independently selected
- bicyclic
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000002950 monocyclic group Chemical group 0.000 abstract 3
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003536 tetrazoles Chemical class 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a compuestos que tienen la estructura 1 donde: (a)R1 es CO2H, C(O) NHOH, CO2R7, CH2OH, S(O)2R7, C(O)2R7, C(O)NHR7, C(O) NHS (O)2R7 o tetrazol,donde R7 o tetrazol, donde R7 es alquilo, heteroalquilo, anillo alifático carbocíclico monocíclico, anillo alifático heterocíclico monocíclico, anilloaromático monocíclico, o anillo heteroaromático monocíclico; (b) W es O, NH, S, S(O), S(O)2, O (CH2)m; donde m es un numero entero de 0 a 3; (c)R2 es H y R3 esH o alquilo inferior, o R2 y R3 juntosforman un enlace covalente; (d)R4 es H, alquilo, heteroalquilo, anillo alifático carbocíclico monocíclico, anilloalifático heterocíclico monocíclico, anillo aromático monocíclico, o anillo heteroaromático monocíclico, siempre que cuando cada R5 y R6es H, R4 sea otro quemetilo; (e) cada R6 se selecciona independientemente del grupo formado por H, CH3, y C2H5; (f) X es NHR8 u OR8, donde cada R8 se selecciona independientementedel grupo formado por H, acilo, alquilo, heteroalquilo, anillo alifático carbocíclico monocíclico, anillo alifático heterocíclico monocíclico, anillo aromáticomonocíclico, y anillo heteroaromático monocíclico; (g) cada R6 se selecciona independientemente del grupo formado por H, CH3, C2H5, OR8 y NHR8; (h)Z es H, metilo, anillo alifático carbocíclico monocíclico, anillo alifático heterocíclico monocíclico, anillo aromático monocíclico, anillo heteroaromático monocíclico,anillo alifático carbocíclico bicíclico, anillo alifático heterocíclico bicíclico, anillo aromático bicíclico, o anillo heteroaromático bicíclico, (i) a y b seseleccionan independientemente del grupo formado por enlace unico, enlace doble is, y enlace doble trans; (j) p es un numero entero de 0 a 6; y cualquierisomero, diastereomero, enantiomero optico de la estructura anterior o una sal farmacéuticamente aceptable, o amida biohidrolizable, éster o imida de ellos.Los compuestos de la presente son utiles para el tratamiento de una variedad de enfermedades y condiciones, tales como trastornos oseos y glaucoma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8007598P | 1998-03-31 | 1998-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR020063A1 true AR020063A1 (es) | 2002-04-10 |
Family
ID=22155104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101444A AR020063A1 (es) | 1998-03-31 | 1999-03-30 | Oximil e hidroxilamino c, prostaglandinas utiles como agonistas de receptores fp y su uso para fabricar medicamentos para tratar oseos y glaucoma. |
Country Status (23)
Country | Link |
---|---|
US (1) | US6410780B1 (es) |
EP (1) | EP1082299B1 (es) |
JP (1) | JP2002509915A (es) |
KR (1) | KR20010042286A (es) |
CN (1) | CN1295560A (es) |
AR (1) | AR020063A1 (es) |
AT (1) | ATE270272T1 (es) |
AU (1) | AU749796B2 (es) |
BR (1) | BR9909267A (es) |
CA (1) | CA2324343C (es) |
DE (1) | DE69918433T2 (es) |
ES (1) | ES2223180T3 (es) |
HU (1) | HUP0102789A2 (es) |
ID (1) | ID26699A (es) |
IL (1) | IL138446A0 (es) |
NO (1) | NO20004904L (es) |
NZ (1) | NZ506853A (es) |
PE (1) | PE20000350A1 (es) |
PL (1) | PL343113A1 (es) |
SK (1) | SK14732000A3 (es) |
TR (1) | TR200002808T2 (es) |
WO (1) | WO1999050241A1 (es) |
ZA (1) | ZA992393B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01008955A (es) | 1999-03-05 | 2002-04-24 | Procter & Gamble | Analogos de prostaglandinas selectivas de fp no saturadas de c16. |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
EP1812017A2 (en) | 2004-10-21 | 2007-08-01 | Duke University | Ophthamological drugs |
US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
CN102101835B (zh) * | 2009-12-16 | 2015-07-22 | 武汉启瑞药业有限公司 | 前列腺素衍生物及其中间体的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3776938A (en) | 1958-05-28 | 1973-12-04 | S Bergstrom | Dihydro-pge1 |
US3636120A (en) | 1967-10-09 | 1972-01-18 | Upjohn Co | Prostaglandin e primary alcohols |
US4011262A (en) | 1972-07-13 | 1977-03-08 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series |
US4024179A (en) | 1972-11-08 | 1977-05-17 | Pfizer Inc. | Substituted ω-pentanorprostaglandins |
DE2460990A1 (de) | 1974-12-21 | 1976-07-01 | Hoechst Ag | Neue prostaglandin-analoga und verfahren zu ihrer herstellung |
GB1507211A (en) | 1975-02-14 | 1978-04-12 | Ono Pharmaceutical Co | Prostaglandin analogues |
JPH0222226A (ja) | 1988-07-12 | 1990-01-25 | Ono Pharmaceut Co Ltd | Pgd類似化合物を有効成分として含有する骨疾患治療剤 |
ES2213504T1 (es) | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. |
-
1999
- 1999-03-22 ES ES99942610T patent/ES2223180T3/es not_active Expired - Lifetime
- 1999-03-22 WO PCT/IB1999/000478 patent/WO1999050241A1/en active IP Right Grant
- 1999-03-22 KR KR1020007010829A patent/KR20010042286A/ko not_active Application Discontinuation
- 1999-03-22 JP JP2000541146A patent/JP2002509915A/ja not_active Withdrawn
- 1999-03-22 ID IDW20002225A patent/ID26699A/id unknown
- 1999-03-22 CA CA002324343A patent/CA2324343C/en not_active Expired - Fee Related
- 1999-03-22 BR BR9909267-0A patent/BR9909267A/pt not_active IP Right Cessation
- 1999-03-22 CN CN99804645A patent/CN1295560A/zh active Pending
- 1999-03-22 EP EP99942610A patent/EP1082299B1/en not_active Expired - Lifetime
- 1999-03-22 US US09/647,381 patent/US6410780B1/en not_active Expired - Fee Related
- 1999-03-22 HU HU0102789A patent/HUP0102789A2/hu unknown
- 1999-03-22 DE DE69918433T patent/DE69918433T2/de not_active Expired - Fee Related
- 1999-03-22 NZ NZ506853A patent/NZ506853A/xx unknown
- 1999-03-22 SK SK1473-2000A patent/SK14732000A3/sk unknown
- 1999-03-22 AT AT99942610T patent/ATE270272T1/de not_active IP Right Cessation
- 1999-03-22 IL IL13844699A patent/IL138446A0/xx unknown
- 1999-03-22 TR TR2000/02808T patent/TR200002808T2/xx unknown
- 1999-03-22 AU AU32701/99A patent/AU749796B2/en not_active Ceased
- 1999-03-22 PL PL99343113A patent/PL343113A1/xx unknown
- 1999-03-29 ZA ZA9902393A patent/ZA992393B/xx unknown
- 1999-03-30 PE PE1999000252A patent/PE20000350A1/es not_active Application Discontinuation
- 1999-03-30 AR ARP990101444A patent/AR020063A1/es unknown
-
2000
- 2000-09-29 NO NO20004904A patent/NO20004904L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2324343A1 (en) | 1999-10-07 |
TR200002808T2 (tr) | 2001-01-22 |
AU749796B2 (en) | 2002-07-04 |
PL343113A1 (en) | 2001-07-30 |
CA2324343C (en) | 2005-05-31 |
KR20010042286A (ko) | 2001-05-25 |
DE69918433D1 (de) | 2004-08-05 |
WO1999050241A1 (en) | 1999-10-07 |
EP1082299B1 (en) | 2004-06-30 |
JP2002509915A (ja) | 2002-04-02 |
ATE270272T1 (de) | 2004-07-15 |
PE20000350A1 (es) | 2000-06-22 |
EP1082299A1 (en) | 2001-03-14 |
IL138446A0 (en) | 2001-10-31 |
ID26699A (id) | 2001-02-01 |
NO20004904D0 (no) | 2000-09-29 |
AU3270199A (en) | 1999-10-18 |
DE69918433T2 (de) | 2005-09-01 |
CN1295560A (zh) | 2001-05-16 |
ZA992393B (en) | 1999-09-03 |
ES2223180T3 (es) | 2005-02-16 |
NO20004904L (no) | 2000-11-29 |
SK14732000A3 (sk) | 2001-04-09 |
NZ506853A (en) | 2002-09-27 |
US6410780B1 (en) | 2002-06-25 |
HUP0102789A2 (hu) | 2001-12-28 |
BR9909267A (pt) | 2000-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR020063A1 (es) | Oximil e hidroxilamino c, prostaglandinas utiles como agonistas de receptores fp y su uso para fabricar medicamentos para tratar oseos y glaucoma. | |
AR016429A1 (es) | Compuesto derivado de acido hidroxamico como inhibidores de metaloproteasa de matriz (mmp), composiciones farmaceuticas y formulaciones veterinarias, usopara la preparacion de composiciones y formulaciones, compuesto intermediario, procedimiento de preparacion del compuesto. | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
RU2291860C3 (ru) | Производные 2-оксо-1-пирролидина, способ их получения и применения | |
CO4970730A1 (es) | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp | |
ES2044874T3 (es) | Derivados del acido malonico y metodos para su sintesis. | |
CO4920242A1 (es) | Compuestos inhibidores de metalopreoteasas 1,4-heterocicli- cos, composiciones farmaceuticas que los contienen y metodos para su utilizacion | |
AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
ES2071621T3 (es) | Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
RU93033485A (ru) | Производные индола, фармацевтическая композиция, способ лечения | |
CO4970731A1 (es) | Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fp | |
ES505960A0 (es) | Un procedimiento para la obtencion de un derivado acilico sustituido del compuesto acido 1,2,3,4-tetrahidro-3-isoqui- nolein-carboxilico | |
CO4970733A1 (es) | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utiles como agonistas fp | |
AR007135A1 (es) | Compuestos de benzofurano y benzopirano, formulaciones farmaceuticas que los contienen y metodos para preparar los compuestos y las formulaciones | |
UY25590A1 (es) | Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos | |
ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
AR014964A1 (es) | Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones | |
JP2004532185A5 (es) | ||
ES2159345T3 (es) | Indazolcarboxamidas. | |
AR018590A1 (es) | Oximil e hidroxilamino c11 prostaglandinas utiles como agonistas de receptores fp y su uso para fabricacion de medicamentos para tratar trastornososeos y glaucoma | |
CO5280081A1 (es) | Antibacterianos de piperidiniloxi oxazolidinona, composicion farmaceutica que los comprende y proceso para su preparacion | |
CO5160251A1 (es) | Analogos de prostaglandinas selectivos del receptor fp c16 insaturados | |
AR009363A1 (es) | Compuestos 3-mercaptoacetilamino-1,5-sustituido--oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz, composicion farmaceutica y usos para la fabricacion de medicamentos para el tratamiento de enfermedades que responden a la inhibicion de metaloproteinasas de la matriz | |
MX9304820A (es) | Derivados de 1, 4-benzodioxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
ES2143181T3 (es) | Derivados biciclicos de isotiourea utiles en terapia. |